Table 3.
Clinical management and outcomes among reported paediatric COVID-19 cases
| Characteristics | Events/total patients | Mean proportion % (95% CI) | Heterogeneity I2 (%) | |
| Clinical management | ||||
| Antibiotics | 1345/3610 |
|
32.2 (25.2 to 40.1) | 41.9 |
| IVIG | 698/3522 | 19.5 (13.5 to 27.2) | 18.4 | |
| Systemic steroids | 801/4229 | 19.3 (14.9 to 24.9) | 23.7 | |
| Antiviral | 527/4019 | 15.3 (11.1 to 20.7) | 4.5 | |
| Mechanical ventilation | 490/5406 | 12.2 (9.7 to 15.3) | 15.5 | |
| Inotropes | 354/3856 | 11.8 (8.3 to 16.4) | 11.5 | |
| Antimalarial | 336/3299 | 9.9 (6.9 to 14.0) | 0.0 | |
| Aspirin | 238/2588 | 9.0 (5.9 to 13.6) | 78.1 | |
| Interferon | 138/2598 | 7.7 (4.9 to 11.8) | 0.0 | |
| Traditional medicine | 22/4229 | 4.0 (2.8 to 5.6) | 38.7 | |
| Clinical outcomes | ||||
| Recovered | 8704/9335 | 88.9 (86.0 to 91.2) | 36.3 | |
| ICU admission | 1359/9335 | 22.9 (17.6 to 29.2) | 37.2 | |
| Deaths | 96/6902 | 3.6 (2.8 to 4.5) | 24.3 | |
ICU, intensive care unit; IVIG, intravenous immunoglobulin.